New Findings in Cancer Described from Shiraz University of Medical Sciences (Cardioprotective effects of deferoxamine in acute and subacute cardiotoxicities of doxorubicin: a randomized clinical trial).

Keywords: Antibiotics; Antidotes; Antineoplastics; Cancer; Cardiology; Cardioprotection; Chelating Agents; Chemotherapy; Clinical Research; Clinical Trials and Studies; Deferoxamine; Deferoxamine Therapy; Doxorubicin Therapy; Drugs and Therapies; Health and Medicine; Hydroxamic Acids; Iron Chelating Agents; Oncology; Pharmaceuticals; Risk and Prevention EN Antibiotics Antidotes Antineoplastics Cancer Cardiology Cardioprotection Chelating Agents Chemotherapy Clinical Research Clinical Trials and Studies Deferoxamine Deferoxamine Therapy Doxorubicin Therapy Drugs and Therapies Health and Medicine Hydroxamic Acids Iron Chelating Agents Oncology Pharmaceuticals Risk and Prevention 612 612 1 04/10/23 20230410 NES 230410 2023 APR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- A new study on cancer is now available. Patients in the intervention groups were pretreated with DFO 8-h intravenous infusion in each chemotherapy course during and after completion of DOX infusion. We aimed to investigate whether deferoxamine (DFO) can prevent acute cardiotoxicity in children with cancer who were treated with DOX as part of their chemotherapy.". [Extracted from the article]

Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)